News

What's Going On With Cardiff Oncology Stock On Tuesday?

On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:

Johnson Outdoors Shares Slide After Q4 Earnings Miss, Hit By Market Challenges And Lower Margins

Johnson Outdoors Inc (NASDAQ:JOUT) shares plunged after the company reported its fourth-quarter 2024 results. The company’s sales grew 9.9% year-over-year to $105.9 million, missing the consensus of $114.99 million. Loss per share was $3.35, missing the consensus loss of $0.98. Gross margin contracted 600 bps to 23.5%, primarily due to higher promotional discounts, a shift in product mix favoring lower-margin items, and inventory reserves for slow-moving and obsolete stock. Gross profit was down